Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in
treating patients who have solid tumors. Interleukin-12 may kill tumor cells by stopping
blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either
kill them or deliver tumor-killing substances to them without harming normal cells. Combining
interleukin-12, chemotherapy, and monoclonal antibody therapy may kill more tumor cells.